- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Dapagliflozin, a feasible alternative to sulphonylureas as an add-on after metformin failure in type 2 diabetes patients
Korea: Dapagliflozin is safe and well-tolerated and, therefore, appears to be a more favourable alternative to sulphonylureas as an add-on therapy after failure of metformin monotherapy in Korean patients with type 2 diabetes, says a recent study published in Diabetes, Obesity and Metabolism.
Findings from the BEYOND study revealed that dapagliflozin reduced total body fat (BF) mass, abdominal subcutaneous adipose tissue (SAT) and visceral adipose tissue (VAT) areas and showed better glycemic control than glimepiride at eek 52 among the Korean population with type 2 diabetes (T2D). Dapagliflozin is an SGLT2 (sodium-glucose cotransporter-2) inhibitor that targets the pathophysiological increase in renal glucose reabsorption and shows promising glucose-lowering effects and more favourable pleiotropic effects on the risk of composite renal and cardiovascular outcomes.
In patients with type 2 diabetes, additional antidiabetic agent(s) are generally added for glycemic control after the failure of first-line metformin monotherapy. International treatment guidelines recommend stepwise therapy, and sulphonylureas (SUs) such as glipizide, gliclazide, and glimepiride can be added to metformin as second-line treatment. Sulphonylureas are frequently associated with adverse effects of hypoglycemia and weight gain, but many modern SUs, such as glimepiride, have better safety profiles.
Dapagliflozin is an SGLT2 (sodium-glucose cotransporter-2) inhibitor that targets the pathophysiological increase in renal glucose reabsorption and shows promising glucose-lowering effects and more favourable pleiotropic effects on the risk of composite renal and cardiovascular outcomes.
Against the above background, Hyeong Kyu Park, Soonchunhyang University College of Medicine, Seoul, Korea, and colleagues aimed to evaluate dapagliflozin's effect on body composition such as total body fat mass, abdominal VAT and SAT areas compared with glimepiride in Korean patients with T2D in a 52-week, multicentre, randomized, parallel-group, open-label, Phase IV study (BEYOND study).
The study included 121 patients with inadequate glycaemic control (glycated haemoglobin ≥7.0% and <10.0%) on metformin monotherapy (≥1000 mg/day). They were randomized in a ratio of 1:1 to receive dapagliflozin 10 mg/day (n=60) or glimepiride 1-2 mg/day (n=61) for 12 months as an addition to metformin therapy. Out of 124 enrolled patients, 106 completed the study. Baseline and end-of-study body composition evaluations included abdominal computed tomography scans and dual-energy X-ray absorptiometry.
The study revealed the following findings:
- Over 52 weeks, the dapagliflozin group showed the following differences versus the glimepiride group: −2.59 kg BF mass, −1.94% BF%, −17.55 cm2 VAT area, −18.39 cm2 SAT area, −0.46% glycated haemoglobin, −18.25 mg/dl fasting blood glucose, −3.7 kg weight, −2.21 cm waist circumference, −1.37 kg/m2 body mass index, −6.81 mmHg systolic blood pressure and +657.71 ng/ml in adiponectin; all were statistically significant.
- Both groups had similar incidences of adverse events; however, hypoglycaemic events were mainly (12 of 15) reported in the glimepiride group.
"The BEYOND study confirms the statistically significant effects of dapagliflozin versus glimepiride as the add-on to metformin in reducing total BF mass and total BF% at week 52 among the Korean population with type 2 diabetes," the researchers wrote.
"Being well tolerated and safe, dapagliflozin is a potentially valuable alternative to sulphonylureas as an add-on after the failure of metformin monotherapy in Korean and other Asian people with T2D," they concluded.
Reference:
Park, Hyeong Kyu, et al. "Effects of Dapagliflozin Compared With Glimepiride On Body Composition in Asian Patients With Type 2 Diabetes Inadequately Controlled With Metformin: the BEYOND Study." Diabetes, Obesity & Metabolism, 2023.
MSc. Biotechnology
Medha Baranwal joined Medical Dialogues as an Editor in 2018 for Speciality Medical Dialogues. She covers several medical specialties including Cardiac Sciences, Dentistry, Diabetes and Endo, Diagnostics, ENT, Gastroenterology, Neurosciences, and Radiology. She has completed her Bachelors in Biomedical Sciences from DU and then pursued Masters in Biotechnology from Amity University. She has a working experience of 5 years in the field of medical research writing, scientific writing, content writing, and content management. She can be contacted at  editorial@medicaldialogues.in. Contact no. 011-43720751
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751